Hygeia Healthcare Holdings Co., Limited (6078.HK) is China's largest oncology-focused healthcare group, owning and operating private for-profit hospitals that provide comprehensive oncology services including radiotherapy, chemotherapy, surgery, targeted therapy, cancer diagnosis, treatment, and rehabilitation; it also offers radiotherapy services to third-party hospitals through consulting, equipment licensing, maintenance, and technical support, alongside hospital management services for private not-for-profit facilities, supply chain operations, and sales of pharmaceuticals, medical consumables, equipment, and proprietary SRT radiotherapy equipment. Founded in 2009 and headquartered in Shanghai, the company primarily serves oncology patients across the People's Republic of China, concentrating operations in the domestic market with a network spanning regions like the Yangtze River Delta and beyond, supported by approximately 8,169 employees. Recent expansions include the openings of Heze Hygeia Hospital and Chongqing Hygeia Hospital in 2024, acquisitions such as a 70% stake in Chang'an Hospital and Datang International (Hong Kong) Limited for CNY 1.2 billion each, an 89.2% stake in Yixing Hygeia Hospital in 2023, and ongoing developments like Wuxi Hygeia Hospital, Changshu Hygeia Hospital, and expansions at Suzhou Yongding Hospital and Qufu Hospital, aiming to grow total hospital beds toward 12,000 by late 2024.